Problems with iPS cells could delay development of treatments

04/1/2011 | Reuters

Experts say the discovery of gene mutations and other abnormalities in induced pluripotent stem cells raise concerns about the safety of the cells and could hamper efforts aimed at using them to develop treatments for various human diseases. Meanwhile, some scientists say iPS cells could fill the research gap into diseases that embryonic stem cells couldn't address. "The beauty of iPS cells for this kind of study is that it gives us the ability to create human neurons with different genetic backgrounds, and specifically with genetic backgrounds with the disease of interest," said Dr. Jack Kessler from Northwestern University.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN